The potentiators' mode of action does not benefit the majority of the CF population who have the Class II F508del-CFTR mutation, as F508del-CFTR is degraded while transitioning through the endoplasmic reticulum, with very little or no mutant protein reaching the apical membrane of epithelial cell. This evidence concerns the gene CFTR and cystic fibrosis.